The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26205
Abstract: AUTHOR CONTRIBUTIONS Musa Yilmaz, Hagop Kantarjian, Naval Daver, Farhad Ravandi designed the study, analyzed the data, and wrote the paper. Musa Yilmaz, Sherry Pierce, Naval Daver, collected and analyzed the data. Sanam Loghavi, Keyur Patel,… read more here.
Keywords: mutational landscape; disease card11; cold agglutinin; agglutinin disease ... See more keywords
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26965
Abstract: Cold agglutinin disease (CAD) is a rare, autoimmune, classical complement pathway (CP)-mediated hemolytic anemia. Sutimlimab selectively inhibits C1s of the C1 complex, preventing CP activation while leaving the alternative and lectin pathways intact. In Part… read more here.
Keywords: complement; agglutinin disease; sutimlimab; treatment ... See more keywords
Multifocal thrombosis with peripheral gangrene in a young boy: Mycoplasma infection triggered cold agglutinin disease.
Sign Up to like & getrecommendations! Published in 2021 at "Immunobiology"
DOI: 10.1016/j.imbio.2021.152075
Abstract: Cold agglutinin disease (CAD) is extremely rare in children. We report an 8-year-old boy who presented with gangrene of right foot with hypertension and absent lower limb pulses. Blood peripheral smear evidence of autoagglutination and… read more here.
Keywords: cad; cold agglutinin; agglutinin; peripheral gangrene ... See more keywords
Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-69465-2
Abstract: Cold agglutinin disease (CAD) is a rare form of autoimmune haemolytic anaemia, and because of its rareness, there is no standard treatment for CAD patients. We retrospectively analysed the response to rituximab-containing therapy in CAD… read more here.
Keywords: containing therapy; disease; cold agglutinin; rituximab containing ... See more keywords
Healthcare resource utilization among patients with cold agglutinin disease in Denmark
Sign Up to like & getrecommendations! Published in 2021 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2021.1960494
Abstract: Abstract Objectives Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia that may manifest in complement-mediated chronic hemolytic anemia, profound fatigue, and transient agglutination-mediated circulatory symptoms. This study compared the healthcare resource… read more here.
Keywords: healthcare resource; among patients; patients cad; cold agglutinin ... See more keywords
Monoclonal antibodies for treatment of cold agglutinin disease
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2023.2209265
Abstract: ABSTRACT Introduction Cold agglutinin disease (CAD) is a difficult-to-treat autoimmune hemolytic anemia and B cell lymphoproliferative disorder associated with fatigue, acrocyanosis, and a risk of thromboembolic events. Cold-induced binding of autoantibody agglutinates red blood cells… read more here.
Keywords: agglutinin disease; complement; antibody based; treatment ... See more keywords
Complement-directed therapy for cold agglutinin disease: sutimlimab.
Sign Up to like & getrecommendations! Published in 2023 at "Expert review of hematology"
DOI: 10.1080/17474086.2023.2218611
Abstract: INTRODUCTION Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia defined as a distinct, low-grade lymphoproliferative disorder and characterized by the presence of immunoglobulin M (IgM) antibodies that recognize the "I" antigen… read more here.
Keywords: cad; agglutinin disease; complement; sutimlimab ... See more keywords
A Rare Case of Autoimmune Hemolytic Anemia Caused by Warm-reacting IgM-class Antibodies Associated with Mycoplasma Pneumoniae Infection
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqaa161.361
Abstract: Warm autoantibodies are usually IgG-class and/or IgA-class immunoglobulins. may be classified as agglutinins or hemolysins, which may be incomplete or complete, depending on in vitro serology; they almost always bind complement. Autoimmune hemolytic anemia with… read more here.
Keywords: anemia; autoimmune hemolytic; class; cold agglutinin ... See more keywords
Concomitant cryoglobulinemic vasculitis and cold agglutinin disease successfully treated with bortezomib
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000014201
Abstract: Rationale: Concomitant cryoglobulinemic vasculitis and cold agglutinin disease (CAD) is an extremely uncommon clinical scenario. The role of bortezomib in the treatment of cryoglobulinemic vasculitis needs further investigation. Patient concerns: A 72-year-old Chinese woman presented… read more here.
Keywords: vasculitis cold; concomitant cryoglobulinemic; cold agglutinin; vasculitis ... See more keywords
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18289
Abstract: Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia (AIHA), which leads to fatigue and acrocyanosis.1– 4 Until recently, treatment of CAD was mainly based on reduction of the Bcell clone by rituximab or… read more here.
Keywords: sustained sutimlimab; sutimlimab response; agglutinin disease; trial ... See more keywords
Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13903
Abstract: Cold agglutinin disease (CAD) is a rare chronic autoimmune haemolytic anaemia, driven mainly by classical complement pathway activation, leading to profound fatigue and poor quality of life. In the Phase 3 CADENZA trial, sutimlimab—a C1s… read more here.
Keywords: patient reported; agglutinin disease; placebo; fatigue ... See more keywords